Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Avoids Settlements, Scores Third Patent Victory In As Many Months

Executive Summary

Pfizer completed a patent litigation hat trick with its successful defense of a generic challenge to Norvasc, proving itself an exception to the recent industry trend of settling patent suits

You may also be interested in...



Pfizer Continues Slow Exubera Roll-Out, Wants To Grow Chantix Market

Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...

Pfizer Continues Slow Exubera Roll-Out, Wants To Grow Chantix Market

Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...

Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition

The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said

UsernamePublicRestriction

Register

LL079488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel